Marcia Belvin - 17 Dec 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role: SVP, Chief Scientific Officer
Signature: /s/ Lloyd Rowland, as Attorney-in-Fact for Marcia Belvin
Issuer symbol: CTMX
Transactions as of: 17 Dec 2023
Net transactions value: $0
Form type: 4
Filing time: 19 Dec 2023, 19:54:36 UTC
Previous filing: 22 Sep 2023
Next filing: 22 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTMX	Common Stock	Options Exercise	$0	+11,250	+7.6%	$0.000000	159,201	17 Dec 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTMX	Performance Stock Units (PSUs)	Options Exercise	$0	-11,250	-50%	$0.000000	11,250	17 Dec 2023	Common Stock	11,250		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents partial vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.
F2	Includes 116,875 restricted stock units.
F3	Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.